The management of chronic autoimmune diseases such as inflammatory bowel disease (IBD) is often accomplished with the utilization of biologic agents. However, new biosimilars are emerging for the treatment of IBD. These biosimilars are molecules highly similar to approved biologic medicines and are comprehensively developed and rigorously tested to ensure that efficacy and safety are similar to the reference product. Unfortunately, both clinicians and patients lack knowledge of biosimilar efficacy and safety, which leads to fewer clinicians prescribing them and patients experiencing feelings of uncertainty and ungrounded negative perceptions toward receiving biosimilars.
This previously recorded CME Outfitters symposium at the Crohn’s & Colitis Congress 2022 will feature an expert panel discussion that defines biosimilar terminology, presents clinical trial data and real-world evidence on the efficacy and safety of biosimilars, and details team-based strategies for enhancing patient-clinician shared decision-making (SDM) regarding the use of biosimilars.
More Information
Faculty:
Edward V. Loftus, Jr., MD (Moderator)
Professor of Medicine
Mayo Clinic College of Medicine
Co-Director, Advanced IBD Fellowship
Mayo Graduate School of Medicine
Consultant, Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, MN
Shubha Bhat, PharmD, MS, BCACP
Clinical Pharmacy Specialist, Gastroenterology
Digestive Disease & Surgery Institute
Cleveland Clinic
Cleveland, OH
Christina Ha, MD, FACG, AGAF
Inflammatory Bowel Disease Center
Mayo Clinic
Scottsdale, AZ
Learning Objectives:
Upon completion of the educational activity, participants should be able to:
- Define terminology related to biosimilar products, including interchangeability, substitution, and switching.
- Assess the efficacy and safety of biosimilars via clinical trial data and real-world evidence in regard to treatment selection for patients with IBD.
- Implement team-based strategies to enhance patient-clinician SDM regarding the use of biosimilars.
Disclosures
Dr. Loftus reports that he is a consultant for AbbVie Inc.; Amgen Inc; Arena Pharmaceuticals; Boehringer Ingelheim; Bristol Myers Squibb; Calibr - California Institute for Biomedical Research; Celgene Corporation; Eli Lilly; Genentech; Gilead Sciences, Inc; Gossamer Bio; Iterative Scopes, Inc; Janssen Therapeutics; Ono Pharmaceutical CO., LT; Pfizer Inc; Scipher Medicine Corporation; Sunovion Pharmaceuticals, Inc; Takeda Pharmaceutical Company Limited; and UCB, Inc. He receives other financial or material support as Chief Medical Editor, Healio. He receives research support from AbbVie Inc.; BIOCOM CRO (Roberts Clinical Trials); Bristol Myers Squibb; Celgene Corporation; Genentech; Gilead Sciences, Inc.; Gossamer Bio; Janssen Therapeutics; Pfizer Inc; Receptos; Takeda Pharmaceutical Company Limited; Theravance; and UCB, Inc. He is also a stock shareholder (directly purchased) in Exact Sciences Corporation.
Dr. Ha reports that she is a consultant and is on the advisory boards for AbbVie, Inc.; Bristol Myers Squibb; Genentech; Index Pharmaceuticals; Janssen; Pfizer Inc.; and Takeda. She received an educational grant from Pfizer Inc. She has also received non-funded research support from AbbVie Inc.; Eli Lilly; Genentech; and Pfizer Inc.
Accreditation Statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.
CME expiration date: Jan. 31, 2023
